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Abstract
Background: Malnutrition is a problem in advanced cancer, particularly ovarian cancer where malignant bowel
obstruction (MBO) is a frequent complication. Parenteral nutrition is the only way these patients can received
adequate nutrition and is a principal indication for palliative home parenteral nutrition (HPN). Giving HPN is
contentious as it may increase the burden on patients. This study investigates patients’ and family caregivers’
experiences of HPN, alongside nutritional status and survival in patients with ovarian cancer and MBO.
Methods: This mixed methods study collected data on participant characteristics, clinical details and body
composition using computed tomography (CT) combined with longitudinal in-depth interviews underpinned by
phenomenological principles. The cohort comprised 38 women with ovarian cancer and inoperable MBO admitted
(10/2016 to 12/ 2017) to a tertiary referral hospital. Longitudinal interviews (n = 57) were carried out with 20 women
considered for HPN and 13 of their family caregivers.
Results: Of the 38 women, 32 received parenteral nutrition (PN) in hospital and 17 were discharged on HPN.
Nutritional status was poor with 31 of 33 women who had a CT scan having low muscle mass, although 10 were
obese. Median overall survival from admission with MBO for all 38 women was 70 days (range 8–506) and for those
17 on HPN was 156 days (range 46–506).
Women experienced HPN as one facet of their illness, but viewed it as a “lifeline” that allowed them to live outside
hospital. Nevertheless, HPN treatment came with losses including erosion of normality through an impact on
activities of daily living and dealing with the bureaucracy surrounding the process. Family caregivers coped but
were often left in an emotionally vulnerable state.
Conclusions: Women and family caregivers reported that the inconvenience and disruption caused by HPN was
worth the extended time they had at home.
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Introduction
Malnutrition is a problem in advanced cancer, affecting
up to 80% of patients [1]. It is a particular problem in
advanced ovarian cancer as a complication affecting be-
tween 20 and 50% of patients is malignant bowel ob-
struction (MBO) [2, 3]. In MBO, the gastrointestinal
system is unable to function normally and the patient’s
ability to digest food and fluids is minimal. The only way
for these patients to receive adequate nutrition is via
parenteral nutrition (PN).
The numbers of patients with cancer receiving home
parenteral nutrition (HPN) in the UK is increasing, par-
ticularly in patients with ovarian cancer [4]. Given these
increasing numbers it is important to know the objective
and subjective benefits. Studies have pointed to improve-
ments of nutritional status for these patients [5]; how-
ever, clear benefits in terms of survival and quality of life
for patients with MBO have yet to be definitively dem-
onstrated. A systematic review examining survival and
quality of life of HPN for people with inoperable MBO
found the quality of evidence, as assessed using GRADE
[6], very low and therefore the effect of HPN on survival
and quality of life continues to be inconclusive [7].
As clear benefits remain equivocal and these patients
have palliative care needs, it is particularly important to
know patient and family carers subjective experience. To
date studies examining patient and family experience
have not directly addressed the situation of people in
MBO receiving HPN, who are unable to administer
HPN themselves due to their state of ill health and it is
the sole source of nutrition given daily [8, 9].
The aim of this study was to investigate the experience
of HPN for women with ovarian cancer and MBO and
their family members acting as caregivers, in the context
of the nutritional status and survival of a cohort of pa-
tients with ovarian cancer and MBO.
Materials and methods
Study design and participant recruitment
This was a mixed method study which included data on
participant characteristics, body composition and clinical
details alongside longitudinal in-depth interviews under-
pinned by phenomenological principles [10]. The study
cohort was comprised of 38 women admitted with ovarian
cancer and inoperable MBO to a tertiary referral cancer
hospital in the North of England between October 2016
and December 2017. In total 20 women and 13 family care-
givers took part in 57 interviews. Patients were recruited
from the tertiary referral centre and family caregivers were
recruited by asking patients to nominate a relative. In-
formed consent was collected from participants. The study
was approved by East of England Cambridge Central
Research Ethics Committee on behalf of the Health
Research Authority National Research Ethics Service.
Study inclusion criteria
Women with ovarian cancer and inoperable MBO re-
ceiving palliative chemotherapy or best supportive care
were included. Patients were considered to have MBO
after review of appropriate cross-sectional imaging by an
oncological radiologist with extensive experience in the
management of ovarian cancer. Findings considered inop-
erable included multilevel obstruction, extensive serosal
disease with no transition point, extensive mesenteric dis-
ease which would prevent bowel mobilisation. A gastro-
intestinal surgical consultation took place in cases
where there was uncertainty regarding operability.
Those who were considered eligible to receive HPN
(26 patients – see Fig. 1) were invited to take part in
interviews; ability to provide informed consent and
converse in English were required.
Context
Patients were started on PN on a ward at a specialised
oncology hospital. HPN discharge was overseen remotely
by a specialist intestinal failure unit situated at another
hospital across the city. The two centres aimed to dis-
charge medically fit patients within 2 weeks. Home dis-
charge took place when, patients’ symptoms related to
MBO were adequately controlled, there was satisfactory
fluid and electrolyte balance with an established PN pre-
scription, the patient’s performance status was stable
and any recommended home care package was in place.
A homecare company supplied equipment, feed, and
employed nurses to connect and disconnect feed. Once
home, patients had a two-hour slot each evening and
morning for nurses to administer and discontinue infu-
sions. The PN was infused overnight, every night. No




Data were collected on patients’ characteristics at the
time of MBO and outcomes that included survival and
total length of time on PN and HPN. Nutritional status
was measured using self-reported height and usual body
weight, weight at the start of PN (Seca scales) or, if un-
available, estimated dry weight and body mass index.
Body composition was assessed by analysing the com-
puted tomography (CT) image taken nearest to the time
of admission with MBO using software (SliceOMatic,
Tomovision, Canada). Single axial images at the level of
the third lumbar (L3) vertebrae were used to measure
total skeletal muscle and total fat mass at the cross-
sectional area. Hounsfield unit thresholds were set at −
190 to − 30 for subcutaneous fat, − 150 to − 50 for visceral
fat, − 190 to − 30 for intramuscular fat and − 29 to 150 for
skeletal muscle. The muscle mass and fat mass were
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calculated using a standard equation [11]. A low
muscle mass was defined as < 38.9cm2/m2 at the L3
muscle [12]. Obesity was defined as a visceral fat
mass above 80.1 cm2 [13].
Qualitative data
Women were interviewed up to four time points; in hos-
pital and subsequently up to three times whilst receiving
HPN. Family caregivers were also interviewed a maximum
of four times. Different topic guides were used with pa-
tients and family caregivers; topic guides were used flex-
ibly allowing the interviewer to explore themes raised by
the interviewee. With participant permission, interviews
were audio-recorded and encrypted at source; interviews
lasted up to 1 h. Interviews were transcribed verbatim.
Data collection continued until saturation of themes
was achieved; determined by analysing data concurrently
in an iterative process of reading and analysing transcripts.
Data collection analysis was underpinned by hermeneutic
phenomenology allowing a transition from the descriptive
to interpretive paradigm [10]. The phenomenon under in-
vestigation was the lived experiences of women on HPN
and the experiences of family caregivers.
Data analysis
Statistical analysis
Descriptive statistics were used to describe participants’
data using SPSS Version 22 (IBM Corp., Armonk, NY,
United States) software.
Qualitative data
Interview transcripts were managed using NVivo Ver-
sion 11 (QSR International Pty Ltd., Doncaster, VIC,
Australia) and they were analysed thematically influ-
enced by principles described by Van Manen [14]. Tran-
scripts were iteratively read to identify and code themes
found in the text. Reading progressed from interpreting
the whole interview to selecting phrases (thematic of the
experience of HPN), to a detailed line by line coding.
From these codes explanatory themes were created.
Similar themes were grouped together to form a hier-
archy of themes and subthemes. Anonymised quotations
were taken from the text for each theme and used in this
paper to show a flavour of the data. Reflection on the
meaning of the text in context was undertaken to cap-
ture motivations, emotions, and drivers from partici-
pants to add an interpretive dimension to the analytical
process.
Rigour was introduced by using reflexivity with
field notes; two researchers (AMS and ES) developed
the coding framework and double coded 10% of in-
terviews. The longitudinal nature of the interviews
allowed an opportunity for participants to reflect on
their previous interviews, facilitating clarification of
meaning and documentation of changes in their
attitudes over time. Moreover, the interpretation of
the data was checked with three women and five
family caregivers to ensure the analysis reflected
their experience.
Fig. 1 Flow chart of patients with MBO considered for HPN taking part in an interview. PN = Parenteral Nutrition. HPN = Home
Parenteral Nutrition
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Results
Over a 15-month period, 38 women with MBO were
identified for inclusion from the clinical recruitment site
in this study, patient characteristics are shown in Table 1.
The median interval from initial diagnosis of ovarian
cancer to the development of bowel obstruction was
27.5 months (range 1–184 months). More than half (22
patients) were considered to have a good performance
status, performance status 0 to 2, whereas 17 patients
had unknown or poor performance status; performance
status 3 and 4. From these 38 women, 26 women were
considered for HPN and 20 were interviewed (Fig. 1).
None of the patients who received HPN developed a line
infection. Characteristics were similar between those
women interviewed and those who were not interviewed.
In addition, 13 family caregivers were recruited. A total
of 57 interviews were conducted, with participants being
interviewed up to four times.
Quantitative data
Nutritional status
Nutritional status of the women at the time of MBO
was poor; body composition measured on CT scans
showed that 30/33 had low muscle mass, and 10/33
women were obese. CT scans were unavailable for
five women. The mean time between CT scan and
date of discharge was 53.41 days (SD ± 63.9). The
Glasgow prognostic score, a marker of systematic in-
flammation used to predict survival in cancer with a
higher score associated with poorer prognosis, was 2
in 21 women, 1 in 14 and 0 in 3 [15]. Details regard-
ing nutritional status are presented in Table 2.
Parenteral nutrition and survival
Of the 38 women in the cohort, 32 received PN; infu-
sions were daily and self-reported oral intake was min-
imal. From 32 patients who received PN, 4 died before
discharge, 17 were discharged on HPN and 11 left with-
out HPN. For the patients that were discharged without
HPN, the reasons were: end of life care (n = 4), assessed
as unsuitable by medical team (n = 3) and patient offered
HPN but declined (n = 4). Median length of receipt of
PN for all 32 women was 54 days (range 2 to 501) and
median length on HPN for 17 women was 91 days
(range 6 to 441).
At the study conclusion 36 of 38 women had died.
Median survival from admission with MBO for all 38
women was 70 days (range 8 to 506). Survival from ad-
mission with MBO for all the 32 women who received
PN was 81 days (range 10 to 506), for the 17 patients
who had HPN was 156 days (range 46–506) (see Fig. 2)






Age, mean ± SD 67 (7.5) 64 (10.1)
Stage at diagnosis
Stage 1 1 2 3 (7.9)
Stage 2 0 1 1 (2.6)
Stage 3 16 15 31 (81.6)
Stage 4 3 0 3 (7.9)
Missing 0 0 0
Histology at diagnosis
Serous 15 16 31 (81.6)
Endometrioid 1 0 1 (2.6)
Clear cell 1 1 2 (5.3)
Mucinous 0 1 1 (2.6)
Adenocarcinoma NOS 2 0 2 (5.3)
Carcinosarcoma 1 0 1 (2.6)
Previous surgery
Total anterior hysterectomy 18 14 32 (82.5)
Bilateral-salpingo-
oophorectomy
17 12 29 (76.3)
Omentectomy 15 14 29 (76.3)
Re-laparotomy 4 4 8 (20.5)
Chemotherapy at BO admission
Total number 12 13 25 (63.0)
Platinum based 7 7 14 (37.0)
ECOG PS at BO admission
0 1 0 1 (2.6)
1 5 3 8 (21.1)
2 7 5 12 (31.6)
3 3 4 7 (18.4)
4 0 1 1 (2.6)
Unknown 4 5 9 (23.7)
No statistical significant differences
ECOG PS Eastern Cooperative Oncology Group performance status
Table 2 Nutritional status of patients with ovarian cancer at the










Fat mass (kg) 21.07 (5.86) 22.94 (7.55) 22.10 (6.7)
Muscle mass (kg) 30.79 (2.88) 32.77 (5.18) 31.83 (4.2)
Muscle Index (cm2/m2) 31.51 (4.49) 33.54 (6.01) 32.59 (5.3)
Missing CT scans 2 3 5
Body Mass Index (kg/m2) 24.10 (6.41) 23.06 (3.72) 23.67 (5.42)
BMI missing 0 4 4
C-reactive protein (mg/l) 62.84 (93.59) 73.44 (67.91) 67.86 (81.5)
Albumin (g/l) 33.10 (6.14) 36.89 (6.40) 34.89 (6.5)
Missing blood results 0 0 0
Sowerbutts et al. BMC Palliative Care          (2019) 18:120 Page 4 of 10
and for 6 women who did not receive PN was 20 days
(range 8 to 109).
Interviews
In total 20 women were interviewed; 11 in hospital and
9 in hospital and up to three times at home (Table 3).
Family caregivers caring for the patients were inter-
viewed on their own where possible so they could freely
express their views; 17 interviews with 13 family care-
givers were conducted without the woman present.
Themes
Four major themes were identified from the data; “com-
peting priorities” as patients experienced PN as one facet
of their illness, “gains”, “losses of normality” and “balan-
cing losses and gains.” Quotations representative of the
emergent themes are given.. Pseudonyms are used for all
participants. For the family caregivers their relationship
to the women is also indicated. Further exemplars of the
themes are given in Additional file 1, all names used are
pseudonyms.
Theme 1 competing priorities
Women described the complexity of their ovarian cancer
journey. They had had many treatments, appointments,
major setbacks and minor annoyances. In one sense HPN
was just another facet of their illness and additional ex-
perience competing for attention amongst many. For ex-
ample, one woman described the irritation she had with
her GP’s surgery. “I sent a sample off to the doctor on
Thursday and they just sat on it for four days … so I’m a
bit annoyed. That’s nothing to do with the feed” (Caroline).
When PN was started in hospital it was unexceptional
for most women, as they generally expressed the view
that in this environment it was normal to undergo inter-
ventions and to be surrounded by medical equipment.
On the ward, PN was administered by the nurse as are
other fluids or drugs and in this setting it is unremark-
able: “they come along and they flush it, and then they
set something up on the drip and they will say, that is
ready for going on” (Betty). One exception was a patient
who focused her anger about not eating on the PN as
she felt receiving nutrition in this way was similar to
being fed like a horse with a nosebag.
In contrast to their experience in hospital, on dis-
charge HPN did stand out as it was unusual to have
medical procedures at home: “initially when this was be-
ing discussed with us … I thought it was probably less
medical than what it is” (Alice, daughter).
Theme 2 gains
Survival Both women and family caregivers viewed
HPN as offering gains. For women, the main advantage
was the extra life it gave them, and this remained so
throughout the course of the interviews: “If I don’t have
the [HPN], I won’t be here. There’s no other way, is
there?” (Kirsten). Women viewed HPN as a ‘lifeline.’ If
they wanted to continue living then nutrition was neces-
sary and HPN was the only way that patients could
receive it: “It’s either die with food or [HPN] for the rest
of your days and I’d sooner live and be on [HPN]” (Sam).
Fig. 2 Survival of patients receiving parenteral nutrition in hospital compared to receiving parenteral nutrition at hospital and home. HPN =
Home Parenteral Nutrition. PN = Parenteral Nutrition
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Quality of life Women perceived HPN as not only im-
proving their quantity, but also quality of life as they
could be out of hospital and at home with friends and
family. As one patient commented: “spending time with
family when you get to, like, my stage, is the most import-
ant for everybody” (Sylvia).
Being at home meant that patients were able to achieve
an element of normality in their lives. It was important for
patients having aspects of life that were unchanged by
their illness. Patients were keen to maintain their ordinary
routine and valued any activities of daily living they were
able to manage, for example one patient appreciated being
able to get out into the garden “I went in the garden the
other day and did a bit of tidying up” (Laura).
Receiving HPN enabled patients to engage in enjoyable
activities, sometimes outside of the home. For a subset
of patients, these activities were goals that they wanted
to achieve such as preparing for Christmas or organising
a family party: “I’ve sorted all Christmas out” (Stacey).
Some patients discussed HPN as having health bene-
fits. They commented that it gave them more energy or
strength: “it’s given me, yes, more energy” (Mabel). Some
thought it stabilised or increased their weight: “I think
I’ve put a little bit of weight on” (Penny).
Family caregivers
Family caregivers echoed the views of patients in that
they saw the principal gain as allowing their relative
extra time. As one husband said “It’s keeping her alive
really. That’s the big advantage.” (John, husband). Two
husbands saw it as giving their wives strength or energy:
“it’s going to help her do what she wants to do” (Derek,
husband).
Caregivers were also appreciative that the treatment
could be given at home as this would facilitate normal-
ity: “I’m looking forward to her being able to come out of
hospital and go home and have the [HPN] at home and,
sort of, have some sort of normality to life” (Alice, daugh-
ter); for example making it easier for friends and neigh-
bours to visit: “our friends and neighbours and relatives
can get easy access to her” (Joseph, husband).
For the family caregivers themselves, the patient being
at home meant they were saved from travelling into the
hospital. For three family caregivers this was a big ad-
vantage as they either lived a long distance away or
could not travel there easily on public transport.
Theme 3 loss of normality
However, the gains that patients and family caregivers
perceived from HPN came at the expense of many losses
to normality.
Curtailment of activities of daily living Disease pro-
gression and HPN gradually eroded patients’ ability to
undertake activities of daily living. A massive loss in pa-
tients’ lives was eating as having MBO meant their oral
intake was minimal.
Disruption to sleep was another problem faced by pa-
tients. HPN was given overnight and patients received
up to three litres of fluid. This volume meant that some
patients needed to make frequent trips to the toilet “It
would be wonderful if I could have even 5 h sleep without
a break” (Marilyn).
Although some patients managed to go out, on the
whole patients’ social lives were curtailed. Some only left
the house for hospital appointments as they did not feel
well enough to go anywhere else. Others would occa-
sionally go out, but for as short a time as possible as they
had a nasogastric tube in place and found it challenging
when people stared at them.
Limiting bodily freedom Patients’ freedom of move-
ment and control of their own bodies were limited by
the physical attachment to HPN and drainage bags.
When commencing HPN, the weight of the feed was a
big issue: “It’s difficult, yeah, especially going upstairs, be-
cause I’ve not got much energy, so usually my husband …
has to take it for me” (Caroline). Even in the morning
when the bag was empty patients found being attached
to it restricting. One family caregiver referred to it as “a
ball and chain” (John, husband).
Table 3 Time, place and numbers of patient and caregivers taking part at each time point
Interview 1 Interview 2 Interview 3 Interview 4 Total
Time from initial discharge 30–48 days 70–110 days 251–329 days
Patient in Hospital (n) 20 1 21
Patient at Home (n) 9 7 2 18
Total 39
Carer at hospital (n) 8 8
Carer at home (n) 5 8 3 1 17
Total 25
n = number of patients or carers taking part at each time point. Thirteen carers and 20 patients took part in 57 interviews. Seven interviews involved more than
one person; either family caregivers were interviewed together or family caregivers and patients
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Moving about attached to tubes and bags was most
problematic for frailer patients. These patients commen-
ted that health care professionals would underplay the
problems that they would have at home: “It wasn’t as
easy as it was made out to be” (Belinda).
However, some patients found the most restrictive as-
pect was their venting gastrostomy. The HPN was only
attached overnight whereas they were only free from the
gastrostomy when they were showering: “when I go in
the shower and everything, I can … take both tubes off,
and I’m a different person” (Kirsten).
Imposed routine In addition to losing their own rou-
tine, patients were subjected to new routines not of their
choosing. They had to deal with the bureaucracy sur-
rounding healthcare services. The patient or family care-
giver needed to be available to receive deliveries of feed.
Patients also had healthcare appointments to attend,
with their oncologist and for monitoring their HPN.
However, the main restriction was the nurses’ home
visits and the patients’ days were scheduled around those
morning and evening visits. Patients found the nurses
cheerful and efficient and no one was critical of nursing
care. Nevertheless, for some the mere presence of the
nurse was a twice daily reminder that they were ill and
the clinical environment imposing itself on their home.
Despite the loss of the patients’ own routines, new
routines were established and became accepted. “It just
becomes a way of life really, you know what I mean, this
is how your day goes and this is what it is. A nurse comes
and takes it off in a morning and then a nurse comes at
night and puts it back on” (Belinda).
Changes to the meaning of home HPN introduced a
myriad of equipment into the home so that it became a
medical environment. One patient was shocked at the
amount of equipment even though she had been told
about it. Prior to starting HPN, some women were con-
cerned where the equipment would go, although they
subsequently managed to accommodate it.
Changing relationships Some women’s relationships
changed when their relative became their main carer.
For most of the women this was their husband. As the
women became unwell they were unable to carry out
some household tasks such as cooking. These tasks fell
to the family caregiver alongside physically caring for the
patient, although assistance was provided by district
nurses and healthcare assistants for frailer patients. Sev-
eral patients commented that their relative did not mind
doing this for them “I’ve done things for him. He can do
things for me” (Michelle), although some recognised that
it caused a strain on their family member. One patient
was keen to protect her husband as much as possible,
remarking about her night-time bathroom visits “I’ve
tried creeping, ‘cause I don’t want to wake him up”
(Penny). Her husband on the other hand was keen to
help: “I’m awake most of the night listening for her, but
she tells me not to help her” (Simon, husband).
Family caregivers
Overall, family caregivers thought HPN was beneficial
for their relative. However, HPN meant that they had to
contend with various losses. Family caregivers reported a
physical toll, for example if they were frail themselves,
carrying heavy HPN bags for patients could be problem-
atic. Some family caregivers reported financial implica-
tions, particularly if they were self-employed: “as for
going out and taking a contract on or something. It’s just
not feasible” (John, husband). Free time for family care-
givers was limited. They were restricted from going out
by the number of healthcare professionals coming to
their home. If the patient and family caregiver did man-
age to get out they needed to be back in time for the
HPN nurses’ arrival. In addition, there were social im-
pacts. For example, as the patient could not eat, hus-
bands ate alone and some had to learn to cook for the
first time: “Not my strong point … No, I burn water”
(Chris, husband). Supporting their relative led to some
family caregivers neglecting their own health: “I am
physically falling to bits” (Scarlett, daughter).
Family caregivers wanted to care for their relative, but
this could sometimes be difficult leading to contradict-
ory statements or attitudes. One husband said that car-
ing is “what you sign on for when you get married”
(Simon, husband). However, at the end of the second
interview, he reported feeling like a “prisoner” being very
limited in the time that he could go out. Moreover, there
were two families who said that they wanted their rela-
tive home as soon as possible. However, when the dis-
charge process was started, they brought up questions
related to the fitness of their relative to cope at home.
Some family caregivers wanted more information.
They felt they received information in an ad hoc manner
if they were present when a healthcare professional vis-
ited a patient, but otherwise they could miss out: “facts
and information had been given to my mum that I
hadn’t been privy [party to] to, I think I should have been
privy [party to] to it” (Alice, daughter).
Theme 4 balancing gains and losses
Stopping HPN Given the losses experienced, patients
were asked if they had thought about stopping the HPN.
Stopping HPN was largely mentioned in a general way
by oncologists, but patients did not seem to take this on
board as they were surprised by the question. Seven of
the nine patients having HPN were unequivocal during
all the interviews they would not stop it: “No, why would
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I do that?” (Laura). The reasons cited by four were they
would be dead or it is keeping them alive. One said that
they would be hungry and another that it had become a
way of life. One patient would perhaps think about it if
she became very unwell in the future: referring to that
time she said: “when I get to the point where I’ve got to say,
oh, enough is enough, it won’t matter then, but until that
point comes then I just have to fight, keep going” (Stacey).
This patient was unusual as a doctor at the intestinal fail-
ure unit had asked her to think about what she wanted to
do in the event of her developing sepsis from a central
venous catheter infection. Another patient, during her sec-
ond interview, referring to stopping, said “I do get the odd
moment when I feel really tired” (Marilyn). However, it
was not something that she had seriously considered. In
subsequent interviews when she was feeling a bit better,
she did not entertain the idea of stopping.
Hope The theme of hope was useful for examining how
patients viewed their lives along their journey of HPN.
Early in the process, some patients were still receiving
chemotherapy and hoped that their condition would im-
prove sufficiently be able to eat again. Such patients
viewed this as a genuine possibility.
Later on, patients hoped for things in a more wistful
way. For example, one patient said she would like to go
on holiday, but realised that this was not possible at her
stage of illness. Another said that she hoped some treat-
ment might be found to deal with the MBO.
Other patients at this stage had more contained or
realistic hopes. One patient hoped for a bit more time
and another that she would be pain free at the end. In
contrast, one woman said that she did not hope for any-
thing. However, on further discussion she was planning
a night away with her two daughters indicating she was
looking forward.
Discussion
This is the first time, to our knowledge, that longitudinal
in-depth interviews have been carried out with people in
MBO receiving HPN, and placed in the context of nutri-
tional status and survival of a cohort of similar ovarian
cancer patients. Patients and family caregivers in this
study viewed HPN as offering benefits in terms of sur-
vival and improving quality of life by enabling patients
to be out of the hospital environment. However, these
benefits were accompanied by many losses to normality.
Overall the experience of HPN for patients and family
caregivers was bittersweet bringing both advantages and
restrictions.
Patients viewed HPN as the lifeline enabling them to
continue living. They had a median of around 3months
on HPN, which concurs with data from other studies
which found a median overall survival of between 60 to
155 days (range 2 to 1278 days) [16–19]. Historically, it
has been found that people are unable to live longer
than approximately 70 days without nutrition [20–23].
Therefore, it is possible that patients living longer than
this period were correctly assuming HPN added to their
lifespan as oral intake was minimal and nutritional needs
were met primarily through HPN.
Interestingly, patients achieved on average 3 months at
home despite the majority having poor nutritional status,
which is known to reduce survival [24]. This length of
survival is in line with current guidance for considering
HPN in advanced cancer patients [25], which also rec-
ommends considering patient quality of life and using
performance measures as an indicator for HPN. In this
cohort over half of the patients had a relatively good
performance status at the time of MBO diagnosis.
For the patients who got home, HPN improved indi-
viduals’ quality of life by enabling them to be out of hos-
pital. This allowed patients to have some normality in
their lives which was appreciated possibly because their
illness had eroded so much of their previous way of life.
These experiences echo those of patients with benign in-
testinal failure on HPN who discuss HPN as a lifeline,
which allows them some normality [8, 26]. There are
also similarities between our findings and patients with
advanced cancer not in MBO having HPN as supple-
mentary nutrition. As with some of the women in our
cohort, HPN was reported as increasing energy and
strength while preventing weight loss [9, 27].
Whilst HPN offered gains, patients also experienced
many losses of normality. Women viewed these losses
in the context of their illness as a whole, but it was
clear that the losses may have been disease-related
such as loss of eating or HPN-specific such as being
connected to the infusion. The theme of loss and the par-
ticular losses women faced resonated with those discussed
in the literature. HPN is experienced in the context of liv-
ing with other symptoms of illness, which may be burden-
some [8, 26, 28]. Other recurring themes are restrictions
imposed from being connected to the HPN and the lack
of autonomous control over their body [8, 26, 29]. Moving
about with the feed was particularly problematic for frailer
patients. For these patients, healthcare professionals need
to be realistic rather than too optimistic about the difficul-
ties ahead when discussing HPN.
In order to assess how burdensome HPN was for pa-
tients, they were asked if they had thought about stopping
it, as patients may consider stopping a treatment that they
find troublesome or that is associated with poor quality of
life [30]. However, for these patients the burden of treat-
ment did not outweigh benefit. Two patients who reflected
on stopping did not seriously consider it as an option at
that point. Most immediately dismissed the idea, which is
consistent with other studies, which have demonstrated
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that patients with advanced cancer do not find HPN more
burdensome than those with benign disease [31].
Hope is an important element for cancer patients cop-
ing with their illness [32]. Studies have found hope to be
high even in advanced cancer patients and loss of hope be-
ing associated with a decreased ability to cope [33, 34].
The patients in this study had hopes, although overtime
this changed from being unrealistic to more circumspect.
However, engaging in hope indicated that patients were
actively living their lives. This is consistent with other
work, which reported that terminally ill patients thought
of themselves as living while dying as long as they could
still participate in day to day activities [35].
Family caregivers agreed with the patients’ views of the
benefits of HPN. However, the burden of caring led some
family caregivers to express feelings of ambivalence. Carer
burden is widely acknowledged and it is recognised that
for some this can give rise to mixed emotions [36, 37].
Also prominent in the literature is the need to involve
family caregivers in clinical decision making [38]. Cur-
rently, family caregivers only receive information if they
happen to be present at a bed-side consultation. Given the
impact of HPN on family caregivers it may be preferable
that they have the opportunity to be present at discussions
relating to the practicalities of treatment.
A strength of this work is the use of longitudinal inter-
views. This method allowed the capture of patient and
family caregiver experiences and changes in attitudes
over time. Given that all the patients had palliative care
needs the recruitment rate was very high. Moreover, we
collected quantitative data on patient characteristics,
body composition and survival to place the interviews in
context. However, a limitation of the study was that the
data collected was from patient diagnosed with bowel
obstruction at one tertiary referral centre and further
work would be needed to show whether it could be gen-
eralisable. Other limitations that this caused were that as
surgery was not performed at the oncology hospital it
was only possible to collect data on the type of oper-
ation. It was not possible to collect accurate data about
whether procedures were performed at the same time
or on different occasions. Also, information has been
given on infection rates as a complication patients may
encounter with HPN; however, data has not been in-
cluded on all hospital readmissions as patients may
have been admitted to a hospital local to their home for
cancer related issues.
Conclusion
In conclusion, from patients’ experiences burden of treat-
ment did not mitigate the benefits of HPN. Motivation to
live outweighed the constraints imposed. Patients and
family caregivers recognise the treatment as a lifeline and
are grateful for it. However, healthcare professionals need
to be alert to the losses that patients will face and present
a realistic picture of them. In the provision of HPN family
caregiver needs and ability to cope over time also need to
be considered. Nevertheless, patients were prepared to
suffer losses to continue living.
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